XORTX re-engages IR Agency after delisting
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
This is a routine corporate announcement with minimal direct market impact. It signals XORTX's continued efforts to maintain investor relations after its TSX delisting, but does not affect its Nasdaq listing or fundamental business prospects.
XORTX Therapeutics Inc., a pharmaceutical company, announced that following the completion of its voluntary delisting from the TSX Venture Exchange, it has re-engaged IR Agency LLC to provide investor relations and marketing services under a consulting agreement with substantially the same terms as previously disclosed in May and August 2026. The company continues to be listed on Nasdaq and is developing several clinical-stage programs for kidney and metabolic diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard